XML 33 R17.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Note 11 - Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2017
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 11. Segment Information: The Company has three reportable segments based on the nature of its products; they are Biotechnology, Protein Platforms and Diagnostics. The Company's Biotechnology reporting segment develops, manufactures and sells proteins, antibodies, immunoassays, flow cytometry products, intracellular signaling products, and biologically active chemical compounds used in biological research. No customer in the Biotechnology segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2017, 2016, and 2015. The Company's Protein Platforms segment develops and commercializes proprietary systems and consumables for protein analysis. This segment was formed in fiscal 2015 with the acquisitions of ProteinSimple and CyVek. No customer in the Protein Platforms segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2017 and 2016. The Company's Diagnostics reporting segment develops and manufactures a range of controls and calibrators used with diagnostic equipment and as proficiency testing tools, as well as other reagents incorporated into diagnostic kits. One customer accounted for approximately 12% and 13% of the Diagnostics segments net sales for the years ended June 30, 2017 and 2015, respectively. No customer in the Diagnostics segment accounted for more than 10% of the segment’s net sales for the years ended June 30, 2016. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. Following is financial information relating to the operating segments (in thousands):
|  | Year Ended June 30, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 364,504 |  |  | $ | 317,340 |  |  | $ | 308,437 |
Protein Platforms |  |  | 91,464 |  |  |  | 77,324 |  |  |  | 66,249 |
Diagnostics |  |  | 107,139 |  |  |  | 104,484 |  |  |  | 77,866 |
Intersegment |  |  | (104 | ) |  |  | (125 | ) |  |  | (306 | )
Consolidated net sales |  | $ | 563,003 |  |  | $ | 499,023 |  |  | $ | 452,246 |
Operating Income |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 175,163 |  |  | $ | 168,613 |  |  | $ | 165,226 |
Protein Platforms |  |  | 9,648 |  |  |  | 3,592 |  |  |  | 4,469 |
Diagnostics |  |  | 28,575 |  |  |  | 30,412 |  |  |  | 23,981 |
Segment operating income |  |  | 213,386 |  |  |  | 202,617 |  |  |  | 193,676 |
Costs recognized upon sale of acquired inventory |  |  | (3,037 | ) |  |  | (5,431 | ) |  |  | (6,952 | )
Amortization of intangibles |  |  | (44,393 | ) |  |  | (29,395 | ) |  |  | (26,169 | )
Stock based compensation |  |  | (14,631 | ) |  |  | (9,430 | ) |  |  | (5,957 | )
Acquisition related expenses |  |  | (25,789 | ) |  |  | (2,761 | ) |  |  | (4,519 | )
Corporate general, selling and administrative expenses |  |  | (4,952 | ) |  |  | (5,007 | ) |  |  | (3,056 | )
Consolidated operating income |  | $ | 120,584 |  |  | $ | 150,593 |  |  | $ | 147,023 |
The Company has some integrated facilities that serve multiple segments. As such, asset and capital expenditure information by reportable segment has not been provided and is not available, since the Company does not produce or utilize such information internally. In addition, although depreciation and amortization expense is a component of each reportable segment’s operating results, it is not discretely identifiable. Following is financial information relating to geographic areas (in thousands):
|  | Year Ended June 30, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 313,195 |  |  | $ | 275,859 |  |  | $ | 245,217 |
EMEA, excluding U.K. |  |  | 125,126 |  |  |  | 103,060 |  |  |  | 104,178 |
U.K. |  |  | 28,401 |  |  |  | 28,307 |  |  |  | 32,309 |
APAC, excluding Greater China |  |  | 41,463 |  |  |  | 38,137 |  |  |  | 24,015 |
Greater China |  |  | 39,078 |  |  |  | 36,199 |  |  |  | 34,933 |
Rest of world |  |  | 15,740 |  |  |  | 17,461 |  |  |  | 11,594 |
Total external sales |  | $ | 563,003 |  |  | $ | 499,023 |  |  | $ | 452,246 |
Long-lived assets |  |  |  |  |  |  |  |  |  |  |  |
United States and Canada |  | $ | 119,859 |  |  | $ | 116,830 |  |  | $ | 117,224 |
Europe |  |  | 14,100 |  |  |  | 14,423 |  |  |  | 11,239 |
China |  |  | 1,165 |  |  |  | 1,109 |  |  |  | 1,286 |
Total long-lived assets |  | $ | 135,124 |  |  | $ | 132,362 |  |  | $ | 129,749 |
External sales are attributed to countries based on the location of the customer or distributor. Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration